Jump to content

SINGLE DOSE OF LUTETIUM FOR mCRPC SAFETY ASSESSMENT


Recommended Posts

There have been a number of previous posts in the forums that explain the new treatment known as lutetium PSMA radionuclide therapy, or LuPSMA.

The Journal of Nuclear Medicine has a recent report about a study on the “Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer”.

The objective of this study was to analyze the safety and efficacy of lutetium PSMA radionuclide therapy.

The study was a multi-centre study conducted in Germany.

Initial results indicate that treatment with Lu‑PSMA is safe and seems to have low early side-effect profile.  A relevant PSA decline was detected in 70 % of patients.

Click here to read the report of this study.

 

Peter MacCallum Cancer Centre is planning a further clinical trial with Lu-PSMA in 2017.

 

Link to post
Share on other sites
×
×
  • Create New...